Trials / Not Yet Recruiting
Not Yet RecruitingNCT05491057
Treatment Patterns of Neratinib in HER2+ EBC in China
A Multicenter, Open-label, Single-arm, Non-interventional Study to Investigate the Treatment Patterns of Nerlynx® (Neratinib) in HER2-positive Early-stage Breast Cancer in China
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 500 (estimated)
- Sponsor
- Pierre Fabre Medicament · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, open-label, single-arm, non-interventional study to investigate the treatment patterns of Neratinib in HER2-positive early-stage breast cancer in China
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Neratinib | Neratinib standard dose 240 mg once daily for 1 year |
Timeline
- Start date
- 2022-09-30
- Primary completion
- 2025-12-30
- Completion
- 2026-06-30
- First posted
- 2022-08-08
- Last updated
- 2022-08-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05491057. Inclusion in this directory is not an endorsement.